Y Intercept Hong Kong Ltd Buys 954,072 Shares of Upstream Bio, Inc. $UPB

Y Intercept Hong Kong Ltd boosted its stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) by 2,049.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,000,631 shares of the company’s stock after buying an additional 954,072 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Upstream Bio were worth $9,006,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC purchased a new position in Upstream Bio during the first quarter worth $115,000. Woodline Partners LP raised its stake in shares of Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after acquiring an additional 30,552 shares during the period. Creative Planning bought a new stake in shares of Upstream Bio in the 2nd quarter worth about $154,000. JPMorgan Chase & Co. lifted its holdings in shares of Upstream Bio by 8.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after acquiring an additional 1,275 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period.

Upstream Bio Stock Performance

Shares of UPB opened at $7.51 on Friday. The firm has a fifty day moving average price of $7.79 and a 200-day moving average price of $14.62. The firm has a market capitalization of $408.69 million, a P/E ratio of -2.58 and a beta of 1.23. Upstream Bio, Inc. has a 12-month low of $5.85 and a 12-month high of $33.68.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%.The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. Analysts predict that Upstream Bio, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on UPB shares. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target on the stock. in a report on Friday, March 27th. Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. JPMorgan Chase & Co. cut Upstream Bio from an “overweight” rating to a “neutral” rating and cut their target price for the company from $35.00 to $8.00 in a research note on Friday, June 12th. Finally, Mizuho reduced their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $33.17.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.